Zynyz (retifanlimab)
Search documents
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)
Businesswire· 2026-03-06 21:42
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces the European Commission Approval of Zynyz (retifanlimab) for First-Line Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC). ...
